WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016060190) THERAPEUTIC AGENT FOR COGNITION DISORDER INDUCED BY AMYLOID β-PROTEIN
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2016/060190 International Application No.: PCT/JP2015/079120
Publication Date: 21.04.2016 International Filing Date: 15.10.2015
IPC:
C07K 7/06 (2006.01) ,A61K 38/00 (2006.01) ,A61K 45/00 (2006.01) ,A61P 25/28 (2006.01) ,A61P 43/00 (2006.01) ,C07K 14/47 (2006.01)
Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY[JP/JP]; Kita 8-jyo Nishi 5-chome, Kita-ku, Sapporo-shi, Hokkaido 0600808, JP
NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY[JP/JP]; 1-1, Tsushima-Naka 1-chome, Kita-ku, Okayama-shi, Okayama 7008530, JP
Inventors: SUZUKI Toshiharu; JP
BAN Saori; JP
INOUE Tsuyoshi; JP
Agent: KOBAYASHI Hiroshi; JP
Priority Data:
2014-21167116.10.2014JP
Title (EN) THERAPEUTIC AGENT FOR COGNITION DISORDER INDUCED BY AMYLOID β-PROTEIN
(FR) AGENT THÉRAPEUTIQUE DESTINÉ AU TROUBLE COGNITIF INDUIT PAR LA β-PROTÉINE AMYLOÏDE
(JA) アミロイドβ蛋白質により誘発される認知障害の治療剤
Abstract: front page image
(EN) The present invention addresses the problem of providing a therapeutic agent for cognition disorders induced by amyloid β-protein, the therapeutic agent functioning by a mechanism in which amyloid β-protein is involved but which is different from conventional mechanisms. This medicinal composition, which is for the treatment of cognition disorders induced by amyloid β-protein, comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of either the peptide according to the invention or a pharmaceutically acceptable ester, amide, prodrug, or salt thereof.
(FR) La présente invention aborde le problème de la fourniture d'un agent thérapeutique destiné au trouble cognitif induit par la β-protéine amyloïde, l'agent thérapeutique fonctionnant par un mécanisme dans lequel la β-protéine amyloïde est impliquée, mais qui est différent des mécanismes habituels. Cette composition médicinale, qui est destinée au traitement de troubles cognitifs induits par la β-protéine amyloïde, comprend un transporteur pharmaceutiquement acceptable et une quantité thérapeutiquement efficace soit du peptide de la présente l'invention, soit d'un de ses esters, amides, promédicaments, ou sels pharmaceutiquements acceptables.
(JA) 本発明は、アミロイドβ蛋白質を作用機序とするが、従来の作用機序とは異なるアミロイドβ蛋白質により誘発される認知障害の治療剤を提供することを課題とする。 本発明は、治療上有効量の本発明のペプチド又はその医薬的に許容可能なエステル、アミド、プロドラッグ若しくは塩及び医薬的に許容可能な担体を含む、アミロイドβ蛋白質により誘発される認知障害の治療のための医薬組成物を提供する。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)